Hospira, Inc.

  • Has This Healthcare Device Innovator Put out the 'For Sale' Sign?

    By Robert Hanley - July 26, 2013 | Tickers: CFN, HSP, ICUI

    ICU Medical’s (NASDAQ: ICUI) share price jumped sharply in early May after media outlets reported potential buyer interest in the medical device specialist.  The company was one of the pioneers of needle-free connector devices that attach multiple syringes to a patient’s catheter, thereby allowing healthcare workers to avoid infection-causing needlepricks.  Its Clave brand of devices has a leading market share in the IV connector segment, thanks to a more »

  • Generics Set to Soar

    By Marshall Hargrave - July 22, 2013 | Tickers: ACT, HSP, MYL, TEVA

    IMS Health pegs the worldwide generic drug market at an impressive $240 billion, which should only grow over the long-term as a large number of branded drugs lose patent protection -- pushing the total generic drug market to over $420 billion in 2016. 

    Other key factors driving generic market growth will be a rapidly aging population and the healthcare reform in he U.S., which will give more people access to more »

  • How Valuable Is a Cheaper Treatment for Arthritis?

    By Kanak Kanti - July 15, 2013 | Tickers: ABBV, AMGN, HSP, JNJ

    Arthritis biologics like Remicade, Enbrel, and Humira are pricy drugs that many of the 50 million American arthritis patients – and hundreds of millions of patients worldwide – might not be able to afford. On the other hand, cheaper generic drugs are not as effective. Now, Hospira (NYSE: HSP) is developing Inflectra, a biosimilar for Remicade, that will be safer and more effective than generic options, but at a fraction of the more »

  • 3 Pharma Companies to Buy for the Long Run

    By Madhukar Dubey - July 1, 2013 | Tickers: BIIB, ELN, HSP, VRX

    According to IMS health report, the global pharmaceutical industry is expected to grow at a CAGR of 4.5% in the next five years to reach $1.20 trillion in 2017, from $963 billion in 2012. To keep pace with the industry's growth, pharmaceutical companies are spending on research and development in order to develop new drugs, and are pursuing various expansion strategies. These companies are also looking to more »

  • Is This Pharmaceutical Giant About To Lose Its Cornerstone Drug?

    By Ryan Guenette - July 1, 2013 | Tickers: ABBV, HSP, JNJ, PFE

    What’s the worst nightmare of all pharmaceutical companies? Generics. They might as well be the grim reaper in the eyes of the brand-name pharmaceuticals. Generics completely destroy the pricing power and monopoly one company possesses on a particular drug, costing that particular company billions in lost revenue. Just one example of the devastating effects generics have on the original patent holding company is displayed in the case of Lipitor more »

  • Michael Price Is Bullish on This Drug Manufacturer

    By Anh HOANG - June 24, 2013 | Tickers: BAX, BDX, HSP

    Editor's Note:The initial article stated Hospira closed their largest plant due to FDA actions. This is incorrect; Hospira shut their plant for scheduled maintenance. This version has been corrected and Motley Fool apologizes for the error.

    At the London Value Investor Conference, famous value investor Michael Price pitched Hospira (NYSE: HSP) as one of his favorite stocks. As of March, Price owned 400,000 Hospira shares. Hospira seems more »

  • Is This Hurting Healthcare Company Priced for a Recovery?

    By Bob Chandler - June 13, 2013 | Tickers: ACT, HSP, MYL

    Nothing interests a value investor more than bad news. Where there's a lack of enthusiasm, there's usually a cheap stock. Hospira (NYSE: HSP), a leading manufacturer of generic specialty injectable drugs and infusion pumps, looked a likely candidate. Since mid-2010, the company has delivered a litany of bad news but instead of a depressed bargain the share's look surprisingly fit.

    A chronic case of unsettling news

    The more »

  • Hedge Fund North Run Capital’s Top Q1 Stock Picks

    By Meena Krishnamsetty - May 28, 2013 | Tickers: AET, BSX, GM, HNT, HSP

    North Run Capital, run by its founders Todd Hammer and Thomas Ellis, recently filed its Q1 13F with the SEC, which describes some of their top equity holdings; we’ll look at the top five. See the original 13F here, and it’s important to note that quantitative analyses have revealed that individual investors can benefit by paying attention to hedge fund activity; discover the secrets of this strategy.

    Let more »

  • Investor’s Dilemma

    By Justin Carley - April 1, 2013 | Tickers: HSP, MPC, VLO

    Whether you are an aggressive, shoot-for-the-moon investor or a conservative coupon clipper, you are constantly faced with an oft-debated investor’s dilemma. While in a perfect world, we would all love to buy companies at 52-week lows AND whose business execution is at an all-time high. However, in reality, it boils down to whether to invest in a company with a rising stock price and improving business outlook, or a more »

  • Patent Cliff a Welcome Event for This Pharma Giant

    By Ted Cooper - February 15, 2013 | Tickers: BAX, HSP, TEVA

    While most pharmaceutical companies dreaded the patent cliff, one company welcomed it. Teva Pharmaceutical Industries  (NYSE: TEVA) is the world's largest integrated pharmaceutical manufacturer. While it does extensive R&D to discover new and innovative drugs, the most stable aspect of the business comes from its generic drugs business. The generic business is getting a large boost from the current spate of patent expirations -- it can now manufacture generic more »

  • Hedge Fund North Run Capital’s Stock Picks for 2013

    By Meena Krishnamsetty - February 13, 2013 | Tickers: ADBE, AET, CIT, GM, HSP

    13F filings are made within several weeks after the end of a quarter and disclose many of the long equity positions held by a hedge fund or other major investor. One way that we use this information to benefit investors is by researching investment strategies derived from our database of filings. For example, the most popular small cap stocks among hedge funds tend to outperform the market; we published the more »

  • The U.S. Economy Contracts! What Now?

    By Justin Carley - February 1, 2013 | Tickers: AAPL, FFIV, HSP

    Unless you are a trader that measures holding periods in days, the short answer is nothing.  The S&P 500 has raced out of the gate to start 2013 and is within a stone’s throw of its all-time high.  The bears continue to be proven wrong, but still find their way into popular media outlets to scare everyone. Even the bulls are attempting to “guess” when the next pullback more »

  • Can This Diversified Healthcare Company Keep Investor’s Portfolios Healthy?

    By Ryan Guenette - January 10, 2013 | Tickers: BAX, BCR, COV, HSP, SYK

    A SWOT analysis is a look at a company’s strengths, weaknesses, opportunities, and threats, and is a tremendous way to gain a detailed and thorough perspective on a company and its future. As the 2012 year draws to a close, I would like to pinpoint on a diversified healthcare company, operating in the medical devices, pharmaceuticals, and biotechnology industries, Baxter International Incorporated (NYSE: BAX).

    <img src="http://stockcharts.com/c-sc/sc?s=BAX&p=D&yr=1&mn=0&dy=0&i=t67902519920&r=1357777999361" />
     

    Strengths:

  • Healthcare Hedge Fund is Selling This Pharma Stock, Should You Too?

    By Meena Krishnamsetty - October 8, 2012 | Tickers: ALKS, HSP, NKTR, PCRX, RIGL

    Between April and June of this year, Orbimed Advisors sold 18% of its shares of Pacira Pharmaceuticals (NASDAQ: PCRX), finishing the second quarter with exactly 2 million shares in its portfolio. According to a more recent 13F filing with the SEC, Orbimed has continued selling shares during the third quarter, and as of September 25th owned just over 1.6 million shares, placing it under the 5% ownership mark more »

  • Is Abbott Labs a Good Stock to Buy Right Now?

    By Meena Krishnamsetty - July 23, 2012 | Tickers: ABT, GSK, HSP, MRK, PFE

    Abbott Laboratories (NYSE: ABT) reported on Wednesday that they had met the Street’s second quarter earnings expectations, increasing diluted earnings 10 percent year-over-year to $1.24 per share. Sales increased 6.7 percent over the second, despite a 4.7 percent hit due to unfavorable exchange rates. Abbott is held by a number of hedge funds, including Roberto MignoneBridger Management and Ricky Sandlers Eminence Capital.

    The company more »

  • Critical Children's Cancer Drug Shortage May Be Forestalled

    By Elizabeth Magill - February 15, 2012 | Tickers: GS, HSP, MYL, NVS

    Kudos to Mylan Inc., Hospira Inc., and Sandoz Inc for Stepping Up

    When Ben Venue Laboratories, the largest of four of the nation’s suppliers of injectable preservative-free methotrexate, voluntarily suspended operations last November because of “significant manufacturing and quality concerns,” the supplies of methotrexate have dwindled gradually to the point where oncologists say they were concerned that there was only a two-weeks supply of the drug at many of more »

  • Hold Off On Hospira

    By Justin Carley - February 14, 2012 | Tickers: BAX, CFN, HSP | Editor's Choice

    Hospira (NYSE: HSP) reported 4Q11 results this morning and shares are up more than 6% as the session nears an end.  The results were awful thanks to a terrible 2011 that was highlighted by FDA warning letters and plant shutdowns.  Actual earnings-per-share for the fourth quarter was -$1.30 due to plant shutdowns and other remediation costs.  So what has the shares moving higher?  First off, the key plant in more »

  • Hospira's Long, Slow Return to Health

    By Robert Fisher - January 23, 2012 | Tickers: HSP

    Generic pharmaceutical manufacturer Hospira (NYSE: HSP) has received several warning letters and negative inspection reports in follow up to some letters from the FDA concerning the operation of two of the company's manufacturing plants. To remedy warnings from the FDA is time consuming and expensive. Currently one of Hospira's largest manufacturing plants has been forced to write off large amounts of product and is shipping at a much more »

  • Price The Market Part 32 - Skip the Financials

    By Glen Bradford - January 7, 2012 | Tickers: ELN, HSP, IBM, ISRG, JNJ

    Begin: Hi, my name is Glen Bradford. Welcome to the Financials part of my quest of Pricing the S&P500. This is the hard stuff, so to speak, as far as I'm concerned. Before I begin you might want to read my brief thoughts here.

    End: I sat down and priced out 20 of these financial companies. After doing so I came to a brief realization... I was not more »